🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “L.” Clear

  1. -, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  2. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  3. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  4. ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  5. Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber

    Istituto Gentili S.r.l.

    Urinary Tract Infections

    phase 3 small molecule active

    1 trial

  6. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  7. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

  8. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  9. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  10. DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  11. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  12. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  13. Doripenem

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ventilator-Associated Pneumonia

    phase 3 small molecule terminated

    1 trial

  14. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  15. Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie

    Disc Medicine

    Delirium

    phase 3 small molecule active

    1 trial

  16. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  17. JNJ-90301900 (NBTXR3)

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Carcinoma, Squamous Cell

    phase 3 small molecule active

    1 trial

  18. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  19. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  20. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  21. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Erectile Dysfunction

    phase 3 small molecule completed

    1 trial

  22. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Schizoaffective Disorder

    phase 3 small molecule completed

    1 trial

  23. Placebo cannabis oil. Components: cannabis granulated flos after (ethanol) extraction of cannabinoids; arachidis oleum raffinatum., TA-CBD 10

    Disc Medicine

    Refractory Epilepsy

    phase 3 small molecule active

    1 trial

  24. Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Ilaris 150 mg/ml solution for injection

    Istituto Gentili S.r.l.

    PAPA syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources